Eli Lilly and Company / Radionetics Oncology Inc.

Radiopharmaceutical oncology (GPCR-targeted small molecule radioligands)

1.9M US cases/yr · $7.5B Projected global radioligand therapy market 2030 (Novartis/Lilly/BMS estimates) · 1400 Pluvicto 2024 global net sales (USD MM, Novartis Lu-177 PSMA benchmark)

Disease Overview

Radioligand therapy (RLT) is a rapidly expanding oncology modality that pairs a tumor-targeting ligand with a therapeutic radioisotope (beta emitters such as Lu-177, or alpha emitters such as Ac-225, Pb-212) to deliver cytotoxic radiation directly to cancer cells expressing a specific surface target. The landscape was catalyzed by Novartis's Lutathera (Lu-177 dotatate, SSTR2-targeted, NET) approved 2018 and Pluvicto (Lu-177 vipivotide tetraxetan, PSMA-targeted, mCRPC) approved 2022 — Pluvicto alone generated $1.4B in 2024 sales and catalyzed a pharma land rush. The National Cancer Institute estimates approximately 1.9 million new US cancer cases annually, with radioligand-eligible populations including metastatic prostate cancer (~50,000 mCRPC), neuroendocrine tumors (~12,000 GEP-NET), and emerging indications in breast, lung, pancreatic, and gastric cancers. Traditional radioligands use peptide-based targeting which limits tumor penetration, pharmacokinetics, and off-target dosimetry. Radionetics's differentiated platform applies small-molecule drug design to GPCR targets — a large underexploited class of tumor-expressed receptors — potentially enabling superior tumor penetration, oral or IV dosing flexibility, improved renal clearance, and broader indication expansion than first-generation peptide ligands. Lilly previously acquired POINT Biopharma ($1.4B, Oct 2023) for its actinium-225 infrastructure, and the Radionetics option formalizes Lilly's small-molecule radiopharm leg.

Competitive Landscape

The radioligand therapy landscape is a pharma consolidation battleground. Approved radioligands: Pluvicto (Lu-177 vipivotide tetraxetan, Novartis) — PSMA-targeted mCRPC, $1.4B 2024 sales; Lutathera (Lu-177 dotatate, Novartis) — SSTR2 NET; Azedra (I-131 iobenguane, Lantheus) — pheochromocytoma; Xofigo (Ra-223 dichloride, Bayer) — bone metastatic prostate cancer. Pharma pipeline consolidation: Lilly acquired POINT Biopharma ($1.4B Oct 2023, actinium-225 and Lu-177 assets including PNT2002 PSMA); BMS acquired RayzeBio ($4.1B Dec 2023, Ac-225 alpha emitters); AstraZeneca acquired Fusion Pharmaceuticals ($2B Mar 2024, FPI-2059 NTSR1). Competing platforms: Ariceum Therapeutics (SSTR2 alpha emitters), Clarity Pharmaceuticals (Cu-64/67 theranostic pairs), Telix Pharmaceuticals (Illuccix PSMA imaging, Pixclara), Perspective Therapeutics (Pb-212 alpha). Radionetics's small-molecule GPCR approach is differentiated from peptide-dominated incumbents and complements Lilly's POINT-derived isotope and manufacturing infrastructure, providing Lilly a $1B call option on a new radiopharm chemistry class.